Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Geographic differences in approach to advanced gastric cancer: Is there a standard approach?

Kim R, Tan A, Choi M, El-Rayes BF.

Crit Rev Oncol Hematol. 2013 Nov;88(2):416-26. doi: 10.1016/j.critrevonc.2013.05.007. Epub 2013 Jun 10. Review.

PMID:
23764501
2.

Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer.

Garrido M, Fonseca PJ, Vieitez JM, Frunza M, Lacave AJ.

Expert Rev Anticancer Ther. 2014 Aug;14(8):887-900. doi: 10.1586/14737140.2014.915194. Epub 2014 Jun 23. Review.

PMID:
24953238
3.

Future perspectives for the development of chemotherapy for advanced gastric cancer: Japanese and global status.

Higuchi K, Tanabe S, Azuma M, Sasaki T, Ishido K, Koizumi W.

Pathobiology. 2011;78(6):334-42. doi: 10.1159/000321700. Epub 2011 Nov 18. Review.

PMID:
22104205
4.

Advancing pharmacological treatment options for advanced gastric cancer.

Sudo K, Yamada Y.

Expert Opin Pharmacother. 2015;16(15):2293-305. doi: 10.1517/14656566.2015.1080238. Epub 2015 Sep 11. Review.

PMID:
26359224
5.

Current questions for the treatment of advanced gastric cancer.

Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA.

Cancer Treat Rev. 2013 Feb;39(1):60-7. doi: 10.1016/j.ctrv.2012.09.007. Epub 2012 Oct 25. Review.

PMID:
23102520
6.

A systematic overview of chemotherapy effects in gastric cancer.

Janunger KG, Hafström L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care..

Acta Oncol. 2001;40(2-3):309-26. Review.

PMID:
11441938
7.

Chemotherapy beyond second-line in advanced gastric cancer.

Kim SM, Park SH.

World J Gastroenterol. 2015 Aug 7;21(29):8811-6. doi: 10.3748/wjg.v21.i29.8811. Review.

8.

A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.

Blum M, Suzuki A, Ajani JA.

Future Oncol. 2011 Jun;7(6):715-26. doi: 10.2217/fon.11.50. Review.

PMID:
21675835
9.

Chemotherapy options for gastric cancer.

Meyerhardt JA, Fuchs CS.

Semin Radiat Oncol. 2002 Apr;12(2):176-86. Review.

PMID:
11979419
10.

Metastatic gastric cancer treatment: Second line and beyond.

Ghosn M, Tabchi S, Kourie HR, Tehfe M.

World J Gastroenterol. 2016 Mar 21;22(11):3069-77. doi: 10.3748/wjg.v22.i11.3069. Review.

11.

The role of chemotherapy in metastatic gastric cancer.

Pasini F, Fraccon AP, DE Manzoni G.

Anticancer Res. 2011 Oct;31(10):3543-54. Review.

PMID:
21965776
12.

[Patient with stomach cancer with metastases. What is the value of chemotherapy?].

Wilke H, Stahl M, Vanhoefer U.

MMW Fortschr Med. 2003 Nov 27;145(48):39-42. German.

PMID:
14724998
13.

[Clinical development of S-1 (TS-1) for advanced gastric cancer].

Wasaburo K, Tanabe S, Higuchi K, Sasaki T, Nakayama N, Mihara S, Nakatani K, Nishimura K, Shimoda T, Azuma M, Katada C, Hanaoka N, Naruke A, Ryu T, Ishido K, Saigenji K.

Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:57-63. Review. Japanese.

PMID:
16897973
14.

[A recent trial of chemo-radiation with S-1 against gastric cancer].

Saikawa Y, Kiyota T, Nakamura R, Wada N, Yoshida M, Kubota T, Kumai K, Shigematsu N, Kubo A, Kitajima M.

Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:99-105. Review. Japanese.

PMID:
16897982
15.

Is there a role for second-line chemotherapy in advanced gastric cancer?

Wesolowski R, Lee C, Kim R.

Lancet Oncol. 2009 Sep;10(9):903-12. doi: 10.1016/S1470-2045(09)70136-6. Review.

PMID:
19717092
16.

[Efficacy of capecitabine/cisplatin chemotherapy after failure of all conventional therapies in patients with advanced gastric cancer].

Nishikawa K, Iwase K, Aono T, Yoshida H, Nomura M, Tamagawa H, Matsuda C, Deguchi T, Kawada J, Higashi S, Umeda S, Deguchi K, Fushimi H, Takagi M, Fukui A, Tanaka Y.

Gan To Kagaku Ryoho. 2013 Jan;40(1):57-60. Japanese.

PMID:
23306918
17.

Molecular targeted therapy for advanced gastric cancer.

Kim JG.

Korean J Intern Med. 2013 Mar;28(2):149-55. doi: 10.3904/kjim.2013.28.2.149. Epub 2013 Feb 27. Review.

18.

Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in locally advanced or metastatic gastric cancer: a single institution experience.

Aitini E, Rabbi C, Mambrini A, Cavazzini G, Pari F, Zamagni D, Cantore M, Pagani M, Sorio M, Lusenti A, Adami F, Smerieri F.

Tumori. 2001 Jan-Feb;87(1):20-4.

PMID:
11669552
19.

Advanced gastric cancer: is there enough evidence to call second-line therapy standard?

Arkenau HT, Saggese M, Lemech C.

World J Gastroenterol. 2012 Nov 28;18(44):6376-8. doi: 10.3748/wjg.v18.i44.6376.

20.

[The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].

Sugimoto N, Narahara H, Sakai D, Yamamoto S, Fumoto S, Yagi T, Imamura F, Iishi H, Tatsuta M.

Gan To Kagaku Ryoho. 2009 Mar;36(3):417-24. Japanese.

PMID:
19295265

Supplemental Content

Support Center